Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sensei Biotherapeutics, Inc. filings document a Nasdaq-listed clinical-stage oncology company, its common stock, and its disclosure obligations around pipeline development, operating results, governance, and capital structure. Material-event reports cover financial results, Regulation FD disclosures, board composition and compensation arrangements, and the completed acquisition of Faeth Therapeutics, including acquired-business financial statements and pro forma combined financial information.
Proxy and governance filings describe shareholder voting matters, director and board matters, equity compensation, preferred stock conversion-related disclosures, authorized-share matters, material agreements, and other capital-structure topics. The filing record also reflects clinical and regulatory disclosure categories for PIKTOR and solnerstotug within the company’s oncology development business.
Sensei Biotherapeutics, Inc. President and CEO Anand Kiran Parikh converted preferred shares received in a merger into common stock. He acquired 761,428 shares of Common Stock through the conversion of 761.428 shares of Series B Preferred Stock, which are convertible into 1,000 common shares each with no expiration date. The Series B Preferred Stock had been issued as consideration when Faeth Holdings Therapeutics, Inc. common stock was converted into the right to receive these preferred shares at the closing of a multi‑step merger involving Faeth and its holding entities.
Sensei Biotherapeutics, Inc. director Saira Ramasastry reported existing derivative holdings in the form of employee stock options linked to the company’s common stock. One option covers 5,929 underlying shares at an exercise price of $5.22 per share and expires on May 10, 2034.
A second option covers 8,718 underlying shares at an exercise price of $1.16 per share and expires on January 24, 2036. Footnotes explain these options were received in exchange for prior Faeth-related stock options pursuant to a February 17, 2026 Agreement and Plan of Merger.
Sensei Biotherapeutics director Stephen M. Hahn reported acquiring common shares through a preferred stock conversion and receiving a new stock option award. On June 15, 2026, 44,763 shares of Common Stock were acquired upon the conversion of 44.763 shares of Series B Preferred Stock, leaving him with 44,763 common shares directly owned.
Separately, on June 12, 2026, Hahn received a stock option for 25,000 shares of Common Stock at an exercise price of $13.00 per share. This option vests in 36 equal monthly installments and is expected to be fully vested by June 12, 2029, subject to his continued service with the company.
Sensei Biotherapeutics, Inc. director Stephen M. Hahn filed an initial ownership report on Form 3. The filing shows his beneficial ownership of Series B Preferred Stock, which is a convertible security linked to the company’s common stock.
Each share of Series B Preferred Stock is convertible into 1,000 shares of common stock and has no expiration date, giving long-term equity exposure rather than a short-term trading position. The filing notes that this preferred stock position arose in connection with a completed merger involving Faeth Holdings Therapeutics, Inc. and related entities, where HoldCo common stock was converted into the right to receive shares of Sensei’s Series B Preferred Stock.
Sensei Biotherapeutics, Inc. reported that President and CEO Anand Kiran Parikh received new equity awards connected to the Faeth Holdings Therapeutics merger. He was granted options to buy 136,884 shares of common stock at $1.16 per share, plus an additional option for 12,320 shares at the same exercise price. He also acquired 761.428 shares of Series B Non-Voting Convertible Preferred Stock, which are convertible into 761,428 shares of common stock. The footnotes explain these awards were received in exchange for Faeth common stock and Faeth stock options under the merger agreement, with vesting schedules that run in monthly installments through early 2027.
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, is rebranding and reshaping its leadership and governance while clarifying its clinical focus. The company terminated an unused at-the-market equity program that had allowed up to $50 million of stock sales. Anand Parikh, Faeth’s co-founder, was named Chairman, President and Chief Executive Officer with a base salary of $680,000 and a target annual bonus equal to 60% of salary, and he becomes the company’s principal executive officer. Brian Stephenson was appointed Chief Financial Officer and principal financial officer, and other finance and accounting roles were formalized. The board saw three directors resign and two new directors, Stephen M. Hahn and Saira Ramasastry, join and receive options to purchase 25,000 shares each under the 2026 Equity Plan. The company changed its corporate name to Faeth Therapeutics, will trade on Nasdaq as “FTH,” and relocated its headquarters to Austin, Texas. A concurrent press release highlighted approximately $200 million in gross proceeds from a February 2026 private placement and upcoming PIKTOR trial readouts, including Phase 2 data in advanced endometrial cancer expected in the second half of 2026.
Sensei Biotherapeutics, Inc. reported that its President & PEO, Gerry Christopher, received a grant of stock options covering 220,000 shares of common stock. The options have an exercise price of $29.89 per share and were approved under the company’s 2026 Equity Incentive Plan after stockholder approval.
According to the vesting terms, 25% of the option vests and becomes exercisable on April 10, 2027, with the remaining shares vesting in 36 equal monthly installments so that the award is fully vested by April 10, 2030, contingent on his continued service with the company.
Sensei Biotherapeutics director Phillip B. Donenberg received a stock option grant covering 12,500 shares of common stock. The option has an exercise price of $11.41 per share and expires on June 9, 2036.
The award vests in 12 equal monthly installments over one year, so it becomes fully vested on June 10, 2027, as long as Donenberg continues to provide service to the company on each vesting date. After this grant, he holds options for 12,500 shares directly.
Sensei Biotherapeutics director Bob Holmen received a grant of stock options for 12,500 shares of Common Stock. The options have an exercise price of $11.41 per share and expire on June 9, 2036. They vest in 12 equal monthly installments over one year, becoming fully vested on June 10, 2027, subject to his continuous service. Following this award, he holds 12,500 options directly.